Literature DB >> 18071987

The surgical management of metastatic spinal disease: prospective assessment and long-term follow-up.

R J Mannion1, M Wilby, S Godward, G Lyratzopoulos, R J C Laing.   

Abstract

The last decade has witnessed a resurgence of interest in the surgical treatment of metastatic spinal disease to compliment radiotherapy. A recent randomized controlled trial looking directly at this issue concluded strongly in favour of a combination of surgical decompression and radiotherapy, and there is now growing enthusiasm for surgery to play a role in the management of these patients. We present a prospective cohort study of 62 patients who presented with metastatic cord or cauda equina compression, and were treated with surgical decompression and fixation where necessary. Patients were treated by one surgeon working in a single unit. They were followed-up long term and were assessed objectively, by clinical assessment and prospective questionnaires that included SF36, visual analogue pain scores and Roland Morris back pain scores. Sixty-two patients with a median age of 62 (22-79 years, 27 male) were included in the study. The commonest primary tumours were breast (26%) and lymphoma (13%). The majority of patients had involvement of thoracic vertebrae (58%). 56% of patients were alive at 1 year and 28% at 3 years, with significant improvements observed in both walking and continence. Similarly, significant improvements were seen in SF36 quality of life scores as well as pain. With careful patient selection, long-term survival and good quality of life can be achieved. However, not every patient is suitable or appropriate for surgery, and the discussion focuses on where the surgical threshold should be set.

Entities:  

Mesh:

Year:  2007        PMID: 18071987     DOI: 10.1080/02688690701593579

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  9 in total

Review 1.  Emergency Neurologic Life Support: Spinal Cord Compression.

Authors:  Kristine H O'Phalen; E Bradshaw Bunney; John W Kuluz
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.210

Review 2.  Emergency neurological life support: spinal cord compression (SCC).

Authors:  Kristine H O'Phelan; E Bradshaw Bunney; Scott D Weingart; Wade S Smith
Journal:  Neurocrit Care       Date:  2012-09       Impact factor: 3.210

3.  Emergency Neurologic Life Support: Spinal Cord Compression.

Authors:  Kristine H O'Phelan
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

4.  Postoperative survival and ambulatory outcome in metastatic spinal tumors : prognostic factor analysis.

Authors:  Kyung Yun Moon; Chun Kee Chung; Tae-Ahn Jahng; Hyun Jib Kim; Chi Heon Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-09-30

Review 5.  A systematic review of MIS and open decompression surgery for spinal metastases in the last two decades.

Authors:  Bhoresh Dhamija; Dheeraj Batheja; Birender Singh Balain
Journal:  J Clin Orthop Trauma       Date:  2021-09-25

6.  Treatment of metastatic spinal cord compression: cepo review and clinical recommendations.

Authors:  S L'espérance; F Vincent; M Gaudreault; J A Ouellet; M Li; A Tosikyan; S Goulet
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

7.  Malignant cord compression: A critical appraisal of prognostic factors predicting functional outcome after surgical treatment.

Authors:  Cornelia Putz; Joost J van Middendorp; Martin H Pouw; Babak Moradi; Rüdiger Rupp; Norbert Weidner; Carl Hans Fürstenberg
Journal:  J Craniovertebr Junction Spine       Date:  2010-07

8.  Prognostic parameters and spinal metastases: a research study.

Authors:  Jefferson W Daniel; José C E Veiga
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

Review 9.  Interventions for the treatment of metastatic extradural spinal cord compression in adults.

Authors:  Reena George; Jenifer Jeba; Govindaraj Ramkumar; Ari G Chacko; Prathap Tharyan
Journal:  Cochrane Database Syst Rev       Date:  2015-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.